Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients

<div>Enrichment analyses of differentially expressed genes (DEGs) between the high- and low-risk groups. (a) Heatmap of DEGs in patients in the high- and low-risk groups based on TNF family-based signature (TFS) risk scores. (b) Gene Ontology (GO) terms and (c) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with the DEGs.</div>

Journal of Immunology Research

fig6

Figure 6

Figure 6: Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients 

Figure 6 | Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients 